Rifaximin

Generic Name: Rifaximin

Brand Names: Xifaxan, Zaxine

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₁N_₃O_₁₁

CAS Number: 80621-81-4

Unique Ingredient Identifier: L36O5T016N

Background: Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...

Indication: Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...

Associated Conditions: Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea

Associated Therapies: -

Clinical Trials

Rifaximin for Functional Dyspepsia

Phase 2

Completed

Conditions: Functional Dyspepsia

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2012-07-17

Last Posted Date: 2015-12-02

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 95

Registration Number: NCT01643083

Locations: 🇨🇳
Queen Mary Hospital, Hong Kong, China

Role of Methane in Glycemic Control

Early Phase 1

Completed

Conditions: Diabetes
Obesity

Interventions: Drug: Neomycin
Drug: Rifaximin

First Posted Date: 2012-07-11

Last Posted Date: 2019-05-02

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 11

Registration Number: NCT01638429

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

Phase 2

Conditions: Hepatitis C

Interventions: Drug: Rifaximin
Drug: Placebo

First Posted Date: 2012-05-22

Last Posted Date: 2016-04-22

Lead Sponsor: Columbia University

Target Recruit Count: 59

Registration Number: NCT01603108

Locations: 🇺🇸
Columbia University Medical Center - NYPH, New York, New York, United States

A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

Not Applicable

Completed

Conditions: Intestinal FDG Uptake

Interventions: Drug: Rifaximin

First Posted Date: 2012-03-02

Last Posted Date: 2017-12-13

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 68

Registration Number: NCT01542541

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Rifaximin as a Modulator of Microbial Translocation and Immune Activation

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Rifaximin

First Posted Date: 2011-11-08

Last Posted Date: 2018-09-10

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 73

Registration Number: NCT01466595

Locations: 🇺🇸
The Ponce de Leon Center CRS (5802), Atlanta, Georgia, United States
🇺🇸
Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago, Illinois, United States
🇺🇸
IHV Baltimore Treatment CRS (4651), Baltimore, Maryland, United States

and more 29 locations

Rifaximin in Fatty Liver Disease

Phase 4

Terminated

Conditions: Nonalcoholic Fatty Liver Disease
NAFLD
Nonalcoholic Steatohepatitis

Interventions: Drug: Rifaximin

First Posted Date: 2011-05-18

Last Posted Date: 2020-10-28

Lead Sponsor: Imperial College London

Target Recruit Count: 15

Registration Number: NCT01355575

Locations: 🇬🇧
Liver Unit, St Mary's Hospital, Imperial College London, London, United Kingdom

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Phase 3

Completed

Conditions: Rectal Cancer

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2011-04-29

Last Posted Date: 2024-05-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 69

Registration Number: NCT01345175

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

Not Applicable

Completed

Conditions: Celiac Disease

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2010-06-07

Last Posted Date: 2022-06-29

Lead Sponsor: Columbia University

Target Recruit Count: 50

Registration Number: NCT01137955

Locations: 🇺🇸
Celiac Disease Center at Columbia University, New York, New York, United States

Study of Rifaximin in Minimal Hepatic Encephalopathy

Phase 1

Completed

Conditions: Minimal Hepatic Encephalopathy

Interventions: Drug: rifaximin

First Posted Date: 2010-02-17

Last Posted Date: 2012-12-11

Lead Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center

Target Recruit Count: 20

Registration Number: NCT01069133

Locations: 🇺🇸
Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States

Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin

Phase 3

Completed

Conditions: Diarrhoea

Interventions: Drug: Rifaximin
Drug: Lactose

First Posted Date: 2009-09-17

Last Posted Date: 2013-11-08

Lead Sponsor: Dr. Philipp Zanger, MD MSc DTM

Target Recruit Count: 258

Registration Number: NCT00979056

Locations: 🇩🇪
Institute of Tropical Medicine, University Hospital of Tübingen, Tübingen, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy